Effects of hot water extract of mangosteen pericarp on vascular function: Re-analysis focusing on factors affecting vascular function

抄録

Purpose: Advanced glycation endproducts (AGEs) are involved in age-related deterioration of vascular function. In our clinical study, we evaluated the vascular stiffness of mangosteen pericarp (water extract of mangosteen: WEM), which has an inhibitory effect on the formation of AGEs, and found a trend toward improvement in vascular stiffness, however the improvement was not significant. Factors that affect vascular function include age, blood glucose, blood pressure, and low-density-lipoprotein-cholesterol (LDL-C) or triglycerides (TG). In the present study, we examined the effect of WEM on vascular flexibility by performing a stratified analysis focusing on factors that affect vascular function. In the present study, we performed a stratified analysis focusing on factors affecting vascular function and examined the effect of WEM on vascular flexibility. Methods: In a previous report, 38 women (19 in the WEM group and 19 in the placebo group) aged 25 to 59 years were administered WEM (200 mg) or a placebo for 12 weeks, and blood tests and vascular function tests were performed before, 4, 8, and 12 weeks after intake in a placebo-controlled, double-blind, randomized, parallel-group comparison study. Whereas, in the present study, we reanalyzed the results of the above studies, focusing on factors affecting vascular function (age, blood glucose, blood pressure, and LDL-C or TG). First, we excluded subjects who exceeded the scope indicated in Attachment 2, "Points to Consider in Preparing Application Forms for Foods for Specified Health Use" of "Permission for Labeling of Foods for Specified Health Use" (Notice No. 109 of April 1, 2020, by the Deputy Director-General of the Consumer Affairs Agency). Next, we reanalyzed the effect of WEM on vascular stiffness by selecting subjects who were at least 30 years of age, had borderline blood glucose, normal hypertension and I-degree hypertension, borderline and mild LDL-C, and normal high and slightly high TG, respectively. Vascular stiffness was assessed by PASESA AVE-1500 (Shisei Datum, Japan), API (Arterial Pressure Index) and AVI (Arterial Velocity Pulse Index) in the right upper arm. Results: Subjects with blood LDL-C levels above (>160 mg/dL) those in the mild disease range were excluded (2 subjects in the WEM group and 4 subjects in the placebo group). Subjects with blood glucose levels of 110 ~ 125 mg/dL, systolic blood pressure of 130 ~ 159 mmHg or diastolic blood pressure of 85 ~ 99 mmHg, and TG of 120-199 mg/dL were not extracted for analysis. There were 7 subjects in the WEM group and 9 subjects in the placebo group with an LDL-C of 120~ 159 mg/dL, but no significant difference in API and AVI. 14 subjects in the WEM intake group and 13 subjects in the placebo group aged 30 years or older could be extracted, and WEM intake significantly reduced API after 8 and 12 weeks of intake. However, there was no difference in AVI. Conclusion: The results of this reanalysis results showed that WEM intake, which inhibits glycation, reduced API in healthy women aged 30 years or older. This suggests that WEM intake alleviates age-related vascular stiffening and maintains flexibility.